TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF”), supporting ...

Tectonic Therapeutic (TECX) stock surges on positive interim data from Phase 1b trial for lead candidate TX45 in patients ...

In a report released yesterday, Tiago Fauth from Wells Fargo reiterated a Buy rating on Tectonic Therapeutic (TECX – Research Report), with a ...

Tectonic Therapeutic (TECX) announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate, ...

Tectonic Therapeutic shares doubled, to $56.80, after the company said it saw positive interim data from a Phase 1b acute hemodynamic clinical trial of its lead product candidate, TX45, a long-acting, ...

The trial's safety results were reassuring, with no serious adverse events or significant changes in vital signs, physical exams, or safety laboratory values post-administration of TX45. Transient ...

TECX stock reached a new 52-week high this week, with shares trading at an impressive $53.6. According to InvestingPro data, analysts maintain a strong buy consensus with price targets ranging from ...

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite turning lower on Thursday. The Dow traded up 0.18% to 44,795.97 while the NASDAQ fell 0.25% to 19,583.83. The S&P 500 also ...

European shares were higher today. The eurozone's STOXX 600 rose 0.6%, Germany's DAX 40 gained 0.2% and France's CAC 40 ...

Nurses and home and health agency owners alike have told us that our AI powered app is a gamechanger. With our recent enterprise wins in this $130 Billion sector 1, we believe that we have a solution ...

Tectonic Therapeutic on Thursday morning reported the successful result of its study testing TX45 in a left-sided heart disease called pulmonary hypertension in heart failure with preserved ejection ...